SkyView Investment Advisors’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$385K Sell
26,400
-13,605
-34% -$180K 0.3% 79
2026
Q1
$551K Buy
40,005
+967
+2% +$14.6K 0.07% 181
2025
Q4
$704K Buy
39,038
+127
+0.3% +$2.28K 0.09% 170
2025
Q3
$721K Buy
38,911
+1,203
+3% +$18.9K 0.09% 166
2025
Q2
$597K Buy
37,708
+970
+3% +$17.3K 0.09% 181
2025
Q1
$714K Buy
36,738
+1,619
+5% +$34.1K 0.11% 160
2024
Q4
$774K Buy
+35,119
New +$676K 0.12% 142

Other funds holding CLBT

SkyView Investment Advisors's CLBT Position: Q2 2026 in Review

SkyView Investment Advisors reduced its Cellebrite (CLBT) stake by 34% in Q2 2026, selling an estimated $180K and leaving 26,400 shares worth $385K. The position accounts for 0.3% of the portfolio, ranked #79.

SkyView Investment Advisors first reported a position in CLBT in Q4 2024 and has held it in 7 quarters since. The position peaked at $774K in Q4 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • SkyView Investment Advisors held 26,400 shares of Cellebrite worth $385K as of Q2 2026.
  • SkyView Investment Advisors sold 13,605 Cellebrite shares in Q2 2026, an estimated $180K.
  • Cellebrite made up 0.3% of SkyView Investment Advisors's portfolio in Q2 2026, its #79 holding.
  • SkyView Investment Advisors first reported a position in Cellebrite in Q4 2024 and has held it in 7 quarters since.
  • SkyView Investment Advisors's Cellebrite position peaked at $774K in Q4 2024.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on SkyView Investment Advisors's 13F filing for Q2 2026, filed 15 Sep 2026.